HC Wainwright Reaffirms “Buy” Rating for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $77.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 455.96% from the stock’s current price.

Several other equities research analysts have also weighed in on the company. Cantor Fitzgerald upped their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Piper Sandler started coverage on Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective for the company. Oppenheimer restated an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Finally, Maxim Group increased their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Stock Up 0.4 %

Capricor Therapeutics stock traded up $0.05 during trading hours on Thursday, hitting $13.85. The stock had a trading volume of 303,282 shares, compared to its average volume of 1,189,616. The company has a 50-day moving average of $16.95 and a two-hundred day moving average of $10.78. The company has a market cap of $629.76 million, a PE ratio of -13.07 and a beta of 3.98. Capricor Therapeutics has a fifty-two week low of $3.52 and a fifty-two week high of $23.40.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Main Street Financial Solutions LLC increased its stake in shares of Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 7,500 shares during the period. SG Americas Securities LLC acquired a new stake in Capricor Therapeutics in the third quarter worth about $133,000. Rhumbline Advisers bought a new stake in Capricor Therapeutics during the 2nd quarter worth about $147,000. The Manufacturers Life Insurance Company acquired a new position in Capricor Therapeutics during the 3rd quarter valued at about $161,000. Finally, Sassicaia Capital Advisers LLC bought a new position in shares of Capricor Therapeutics in the 3rd quarter valued at about $192,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.